Nathan C Bahr1, Anil A Panackal2, Michelle M Durkin3, Melinda L Smedema3, Wesley Keown3, Thomas E Davis4, Luke Raymond-Guillen5, Yoon-Dong Park2, Kieren A Marr6, Bettina C Fries7, Peter R Williamson2, David R Boulware8, L Joseph Wheat3. 1. Division of Infectious Diseases, Department of Medicine, University of Kansas, Kansas City, Kansas. 2. Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 3. MiraVista Diagnostics, Indianapolis, Indianapolis, Indiana. 4. Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana. 5. Division of Infectious Diseases, Department of Medicine, Indiana University, Indianapolis, Indiana. 6. Division of Infectious Disease, Department of Medicine Johns Hopkins, Baltimore, Maryland. 7. Division of Infectious Disease, Department of Medicine, Stony Brook School of Medicine, Stony Brook, New York. 8. Division of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND/ OBJECTIVES: Antibody detection is commonly used for diagnosis of histoplasmosis, and cross-reactions have been recognised due to endemic mycoses but not cryptococcosis. We observed cross-reactions in an anti-Histoplasma antibody enzyme immunoassay (EIA) in the cerebrospinal fluid (CSF) from a patient with cryptococcal meningitis and sought to assess the risk of cross-reactive anti-Histoplasma antibodies in persons with cryptococcal meningitis. METHODS: An anti-cryptococcal antibody EIA was developed to measure CSF antibody response in HIV-infected subjects from Kampala, Uganda and previously healthy, HIV-negative subjects at the National Institutes of Health (NIH) with cryptococcal meningitis. Specimens were tested for cross-reactivity in assays for IgG anti-Histoplasma, anti-Blastomyces and anti-Coccidioides antibodies. RESULTS: Among 61 subjects with cryptococcal meningitis (44 Kampala cohort, 17 NIH cohort), elevated CSF anti-cryptococcal antibody levels existed in 38% (23/61). Of the 23 CSF specimens containing elevated anti-cryptococcal antibodies, falsely positive results were detected in antibody EIAs for histoplasmosis (8/23, 35%), coccidioidomycosis (6/23, 26%) and blastomycosis (1/23, 4%). Overall, 2% (2/81) of control CSF specimens had elevated anti-cryptococcal antibody detected, both from Indiana. CONCLUSIONS: Cryptococcal meningitis may cause false-positive results in the CSF for antibodies against Histoplasma, Blastomyces and Coccidioides. Fungal antigen testing should be performed to aid in differentiating true- and false-positive antibody results in the CSF.
BACKGROUND/ OBJECTIVES: Antibody detection is commonly used for diagnosis of histoplasmosis, and cross-reactions have been recognised due to endemic mycoses but not cryptococcosis. We observed cross-reactions in an anti-Histoplasma antibody enzyme immunoassay (EIA) in the cerebrospinal fluid (CSF) from a patient with cryptococcal meningitis and sought to assess the risk of cross-reactive anti-Histoplasma antibodies in persons with cryptococcal meningitis. METHODS: An anti-cryptococcal antibody EIA was developed to measure CSF antibody response in HIV-infected subjects from Kampala, Uganda and previously healthy, HIV-negative subjects at the National Institutes of Health (NIH) with cryptococcal meningitis. Specimens were tested for cross-reactivity in assays for IgG anti-Histoplasma, anti-Blastomyces and anti-Coccidioides antibodies. RESULTS: Among 61 subjects with cryptococcal meningitis (44 Kampala cohort, 17 NIH cohort), elevated CSF anti-cryptococcal antibody levels existed in 38% (23/61). Of the 23 CSF specimens containing elevated anti-cryptococcal antibodies, falsely positive results were detected in antibody EIAs for histoplasmosis (8/23, 35%), coccidioidomycosis (6/23, 26%) and blastomycosis (1/23, 4%). Overall, 2% (2/81) of control CSF specimens had elevated anti-cryptococcal antibody detected, both from Indiana. CONCLUSIONS:Cryptococcal meningitis may cause false-positive results in the CSF for antibodies against Histoplasma, Blastomyces and Coccidioides. Fungal antigen testing should be performed to aid in differentiating true- and false-positive antibody results in the CSF.
Authors: Renee Donahue Carlson; Melissa A Rolfes; Kate E Birkenkamp; Noeline Nakasujja; Radha Rajasingham; David B Meya; David R Boulware Journal: Metab Brain Dis Date: 2014-01-09 Impact factor: 3.584
Authors: David R Boulware; David B Meya; Tracy L Bergemann; Darlisha Williams; Irina A Vlasova-St Louis; Josh Rhein; Jack Staddon; Andrew Kambugu; Edward N Janoff; Paul R Bohjanen Journal: J Acquir Immune Defic Syndr Date: 2010-12 Impact factor: 3.731
Authors: David R Boulware; David B Meya; Conrad Muzoora; Melissa A Rolfes; Katherine Huppler Hullsiek; Abdu Musubire; Kabanda Taseera; Henry W Nabeta; Charlotte Schutz; Darlisha A Williams; Radha Rajasingham; Joshua Rhein; Friedrich Thienemann; Melanie W Lo; Kirsten Nielsen; Tracy L Bergemann; Andrew Kambugu; Yukari C Manabe; Edward N Janoff; Paul R Bohjanen; Graeme Meintjes Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245
Authors: David Zhuang; Chadi Hage; Magdia De Jesus; Emily Hackett; Michelle Durkin; Thomas E Davis; Arturo Casadevall; L Joseph Wheat Journal: Clin Vaccine Immunol Date: 2007-12-12
Authors: Andrew Kambugu; David B Meya; Joshua Rhein; Meagan O'Brien; Edward N Janoff; Allan R Ronald; Moses R Kamya; Harriet Mayanja-Kizza; Merle A Sande; Paul R Bohjanen; David R Boulware Journal: Clin Infect Dis Date: 2008-06-01 Impact factor: 9.079
Authors: Lindsey B Rosen; Alexandra F Freeman; Lauren M Yang; Kamonwan Jutivorakool; Kenneth N Olivier; Nasikarn Angkasekwinai; Yupin Suputtamongkol; John E Bennett; Vasilios Pyrgos; Peter R Williamson; Li Ding; Steven M Holland; Sarah K Browne Journal: J Immunol Date: 2013-03-18 Impact factor: 5.422
Authors: Nathan C Bahr; George A Sarosi; David B Meya; Paul R Bohjanen; Sarah M Richer; Samantha Swartzentruber; Ryan Halupnick; Deidre Jarrett; L Joseph Wheat; David R Boulware Journal: Med Mycol Date: 2015-11-02 Impact factor: 4.076
Authors: David R Boulware; David B Meya; Tracy L Bergemann; Darin L Wiesner; Joshua Rhein; Abdu Musubire; Sarah J Lee; Andrew Kambugu; Edward N Janoff; Paul R Bohjanen Journal: PLoS Med Date: 2010-12-21 Impact factor: 11.069
Authors: Sarah M Richer; Melinda L Smedema; Michelle M Durkin; T Tristan Brandhorst; Chadi A Hage; Patricia A Connolly; Diane S Leland; Thomas E Davis; Bruce S Klein; L Joseph Wheat Journal: Clin Vaccine Immunol Date: 2013-11-27
Authors: Kaitlin Benedict; Jeremy A W Gold; Stephanie Dietz; Seher Anjum; Peter R Williamson; Brendan R Jackson Journal: Open Forum Infect Dis Date: 2022-05-16 Impact factor: 4.423